Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?

Christopher J. Chin

科研成果: 期刊稿件 › 文章 › 同行评审

3 引用（Scopus）

源语言	英语
页（从-至）	289-290
页数	2
期刊	Laryngoscope
卷	127
期	2
DOI	https://doi.org/10.1002/lary.26363
出版状态	已出版 - 2月 1 2017
已对外发布	是

!!!ASJC Scopus Subject Areas

耳鼻喉科学

访问文件

10.1002/lary.26363

其它文件与链接

引用此

@article{43eef2d0c1e5459d976da29b9c80245f,

title = "Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?",

author = "Chin, {Christopher J.}",

year = "2017",

month = feb,

day = "1",

doi = "10.1002/lary.26363",

language = "English",

volume = "127",

pages = "289--290",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?

AU - Chin, Christopher J.

PY - 2017/2/1

Y1 - 2017/2/1

UR - http://www.scopus.com/inward/record.url?scp=84999808832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999808832&partnerID=8YFLogxK

U2 - 10.1002/lary.26363

DO - 10.1002/lary.26363

M3 - Article

C2 - 27796042

AN - SCOPUS:84999808832

SN - 0023-852X

VL - 127

SP - 289

EP - 290

JO - Laryngoscope

JF - Laryngoscope

IS - 2

ER -